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A B S T R A C T   
This work validates the generalizability of MRI-based classification of Alzheimer’s disease (AD) patients and 
controls (CN) to an external data set and to the task of prediction of conversion to AD in individuals with mild 
cognitive impairment (MCI). 
We used a conventional support vector machine (SVM) and a deep convolutional neural network (CNN) 
approach based on structural MRI scans that underwent either minimal pre-processing or more extensive pre- 
processing into modulated gray matter (GM) maps. Classifiers were optimized and evaluated using cross- 
validation in the Alzheimer’s Disease Neuroimaging Initiative (ADNI; 334 AD, 520 CN). Trained classifiers 
were subsequently applied to predict conversion to AD in ADNI MCI patients (231 converters, 628 non- 
converters) and in the independent Health-RI Parelsnoer Neurodegenerative Diseases Biobank data set. From 
this multi-center study representing a tertiary memory clinic population, we included 199 AD patients, 139 
participants with subjective cognitive decline, 48 MCI patients converting to dementia, and 91 MCI patients who 
did not convert to dementia. 
AD-CN classification based on modulated GM maps resulted in a similar area-under-the-curve (AUC) for SVM 
(0.940; 95%CI: 0.924–0.955) and CNN (0.933; 95%CI: 0.918–0.948). Application to conversion prediction in 
MCI yielded significantly higher performance for SVM (AUC = 0.756; 95%CI: 0.720 − 0.788) than for CNN (AUC 
= 0.742; 95%CI: 0.709 − 0.776) (p < 0.01 for McNemar’s test). In external validation, performance was slightly 
decreased. For AD-CN, it again gave similar AUCs for SVM (0.896; 95%CI: 0.855–0.932) and CNN (0.876; 95%CI: 
0.836–0.913). For prediction in MCI, performances decreased for both SVM (AUC = 0.665; 95%CI: 
0.576 − 0.760) and CNN (AUC = 0.702; 95%CI: 0.624 − 0.786). Both with SVM and CNN, classification based on 
modulated GM maps significantly outperformed classification based on minimally processed images (p = 0.01). 
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Deep and conventional classifiers performed equally well for AD classification and their performance 
decreased only slightly when applied to the external cohort. We expect that this work on external validation 
contributes towards translation of machine learning to clinical practice.   
Introduction 
The diagnostic process of dementia is challenging and takes a sub-
stantial period of time after the first clinical symptoms arise: on average 
2.8 years in late-onset and 4.4 years in young-onset dementia (Van Vliet 
et al., 2013). The window of opportunity for advancing the diagnostic 
process is however much larger than these few years. For Alzheimer’s 
disease (AD), the most common form of dementia, there is increasing 
evidence that disease processes start 20 years or more ahead of clinical 
symptoms (Gordon et al., 2018). Advancing the diagnosis is essential to 
support the development of new disease modifying treatments, since 
late treatment is expected to be a major factor in the failure of clinical 
trials (Mehta et al., 2017). In addition, early and accurate diagnosis have 
great potential to reduce healthcare costs as they give patients access to 
supportive therapies that help to delay institutionalization (Prince et al., 
2011). 
Machine learning offers an approach for automatic classification by 
learning complex and subtle patterns from high-dimensional data. In AD 
research, such algorithms have been frequently developed to perform 
automatic diagnosis and predict the future clinical status at an indi-
vidual level based on biomarkers. These algorithms aim to facilitate 
medical decision support by providing a potentially more objective 
diagnosis than that obtained by conventional clinical criteria (Klöppel 
et al., 2012; Rathore et al., 2017). A large body of research has been 
published on classification of AD and its prodromal stage, mild cognitive 
impairment (MCI) (Ansart et al., 2021; Wen et al., 2020; Rathore et al., 
2017; Arbabshirani et al., 2017; Falahati et al., 2014; Bron et al., 2015). 
Overall, classification methods show high performance for classification 
of AD patients and control participants with an area under the receiver- 
operating characteristic curve (AUC) of 85–98%. Reported perfor-
mances are somewhat lower for prediction of conversion to AD in pa-
tients with MCI (AUC: 62–82%). Structural T1-weighted (T1w) MRI to 
quantify neuronal loss is the most commonly used biomarker, whereas 
the support vector machine (SVM) is the most commonly used classifier. 
Following the trends and successes in medical image analysis and ma-
chine learning, neural network classifiers - convolutional neural net-
works (CNN) in particular - have increasingly been used since few years 
(Wen et al., 2020; Cui and Liu, 2019; Basaia et al., 2019), but have not 
been shown to significantly outperform conventional classifiers. Most 
CNN studies perform no to minimal pre-processing of the structural MRI 
scans as input for their classifier (Wen et al., 2020; Basaia et al., 2019; 
Hosseini-Asl et al., 2018; Vieira et al., 2017), while others use more 
extensive pre-processing strategies proven successful for conventional 
classifiers, such as gray matter (GM) density maps (Cui and Liu, 2019; 
Suk et al., 2017). Although CNNs are designed to extract high-level 
features from raw imaging data, it is imaginable that the learning pro-
cess for complex tasks is improved by dedicated pre-processing that 
enhances disease-related features, which reduces model complexity and 
enables a more stable learning process. It is unclear yet whether CNNs 
would improve AD classification over conventional classifiers and 
whether they benefit from extensive MRI pre-processing. 
Despite high performance of machine learning diagnosis and pre-
diction methods for AD, it is largely unknown how these algorithms 
would perform in clinical practice. A next step would be to assess the 
generalizability of classification methods from a specific research pop-
ulation to another study population. There are however only very few 
studies assessing classification performance on an external data set (Wen 
et al., 2020; Bouts et al., 2019; Archetti et al., 2019; Hall et al., 2015). 
Results varied from only a minor reduction in performance for some 
experiments (Wen et al., 2020; Hall et al., 2015) to a severe drop for 
others (Bouts et al., 2019; Archetti et al., 2019; Wen et al., 2020). While 
generalizability seemed related to how well the training data repre-
sented the testing data (e.g. an external data set with similar inclusion 
criteria showed a smaller performance drop than a data set with very 
different criteria (Wen et al., 2020)), a better understanding is crucial 
before applying such methods in routine clinical practice. 
Therefore, this work aims to assess the generalizability of MRI-based 
classification performance to an external data set representing a tertiary 
memory clinic population for both diagnosis of AD and prediction of AD 
in individuals with MCI. To evaluate the value of neural networks and to 
determine their optimal MRI pre-processing approach, we compare a 
CNN with a conventional SVM classifier using two pre-processing ap-
proaches: minimal pre-processing using only rough spatial alignment 
and more extensive pre-processing into modulated GM maps. First, we 
optimize the methods using a large research cohort and assess classifi-
cation performance using cross-validation. Subsequently, we validate 
AD prediction performance in MCI patients of the same cohort as well as 
AD diagnosis and prediction performance in the external data set. 
Methods 
Study population 
We used data from two cohorts. The first group of 1715 participants 
was included from the Alzheimer’s Disease Neuroimaging Initiative 
(ADNI; adni.loni.usc.edu). The ADNI was launched in 2003 as a pub-
lic–private partnership, led by Principal Investigator Michael W. 
Weiner, MD. The primary goal of ADNI has been to test whether clinical 
and neuropsychological assessment, serial magnetic resonance imaging 
(MRI), positron emission tomography (PET), and other biological 
markers can be combined to measure the progression of mild cognitive 
impairment (MCI) and early Alzheimer’s disease (AD). For up-to-date 
information, see www.adni-info.org. We included all participants 
with a T1w MRI scan at baseline from the ADNI1/GO/2 cohorts: 336 AD 
patients, 520 control participants (CN), 231 mild cognitive impaired 
(MCI) patients who converted to AD within 3 years (MCIc) and 628 MCI 
patients who did not convert (MCInc). The CN group consisted of 414 
cognitively normal participants and 106 participants with subjective 
cognitive decline (SCD). Demographics are shown in Table 1. A list of 
included participants is made available at https://gitlab.com/radiolo 
gy/neuro/bron-cross-cohort3. 
The second group of participants was included from the Health-RI 
Parelsnoer Neurodegenerative Diseases Biobank (PND; www.health-ri. 
nl/parelsnoer), a collaborative biobanking initiative of the eight uni-
versity medical centers in the Netherlands (Manniën et al., 2017). The 
Parelsnoer Neurodegenerative Diseases Biobank focuses on the role of 
biomarkers on diagnosis and the course of neurodegenerative diseases, 
Table 1 
Demographics for the ADNI data set.   
AD CN MCIc MCInc 
# participants 336 520 231 628 
male/ female 186/ 150 252/ 268 141/ 90 367/ 261 
age (y; mean±std)  74.9 ± 7.8  74.2 ± 5.8  73.7 ± 7.0  72.9 ± 7.8   
3 https://doi.org/10.5281/zenodo.4896966 
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in particular of Alzheimer’s disease (Aalten et al., 2014). It is a pro-
spective, multi-center cohort study, focusing on tertiary memory clinic 
patients with cognitive problems including dementia. Patients are 
enrolled from March 2009 and followed annually for two to five years. 
In the PND biobank, a total of 1026 participants have been included. 
Inclusion criteria for the current research were: a high resolution T1w 
MRI at baseline, clinical consult at baseline, 90 days or less between MRI 
and clinical consult, and a baseline diagnosis of SCD, MCI, or dementia 
due to AD. A flow diagram of the inclusion can be found in the sup-
plementary files (Fig. S1). A total of 557 participants met inclusion 
criteria. One person was excluded because image analysis failed. This 
led to inclusion of 199 AD patients and 138 participants with SCD. Of the 
MCI group, we included the 139 participants that had a follow-up period 
of at least 6 months. Of this group, 48 MCI patients converted towards 
dementia within the available follow-up time and 91 MCI patients 
remained stable. Demographics are shown in Table 2. 
Imaging data 
We used baseline T1w structural MRI acquired at 1.5T or 3T. 
Acquisition protocols are previously described (ADNI: Jack et al. (2008); 
Jack et al. (2015), PND: Aalten et al. (2014)). Variation in acquisition 
protocols used in PND is detailed in Table 3. For the majority of scans, a 
8-channel head coil was used (N = 423; 76%); other scans used a 16- 
channel (N = 27), 24-channel (N = 1), 40-channel (N = 1), or un-
known coil (N = 104). 
Image pre-processing 
We evaluated two pre-processing approaches based on T1w images: 
minimal pre-preprocessing and a more extensive pre-processing into 
modulated GM maps. 
To prepare T1w images with minimal pre-processing, scans were 
non-uniformity corrected using the N4 algorithm (Tustison et al., 2010) 
and subsequently transformed to MNI-space using registration of brain 
masks with a similarity transformation. A similarity transformation is a 
rigid transformation including isotropic scaling. Registrations were 
performed with Elastix registration software (Klein et al., 2010; Sha-
monin et al., 2014). To account for variations in signal intensity, images 
were normalized within the brain mask to have zero mean and unit 
variance. 
To obtain modulated GM maps encoding gray matter density, the Iris 
pipeline was used (Bron et al., 2014). To compute these maps a group 
template space was defined using a procedure that avoids bias towards 
any of the individual T1w images using pairwise registration (Seghers 
et al., 2004). The pairwise registrations were performed using a simi-
larity, affine, and nonrigid B-spline transformation model consecutively. 
We selected a subset of images for the definition of the template space. 
This template set consisted of the images of 50 ADNI participants that 
were randomly selected preserving the ratio between diagnostic groups 
(subject list available at https://gitlab.com/radiology/neuro/bron-cro 
ss-cohort3). The other images of both ADNI and PND data sets were 
registered to the template space following the same registration pro-
cedure. For the current work, some changes to the template space con-
struction procedure as used in Bron et al., 2014 were made: non- 
uniformity correction was performed, skull-stripping was performed, 
and the template space corresponded to MNI-space. Using similarity 
registration based on brain masks, we computed the coordinate trans-
formations of MNI space to each of the template set’s images, which 
were subsequently concatenated with the pairwise transformations 
before averaging. After template space construction, probabilistic GM 
maps were obtained with the unified tissue segmentation method of 
SPM8 (Statistical Parametric Mapping) (Ashburner and Friston, 2005). 
To obtain the final feature maps, probabilistic GM maps were trans-
formed to the template space and modulated, i.e. multiplied by the Ja-
cobian determinant of the deformation field, to take compression and 
expansion into account (Ashburner and Friston, 2000). To correct for 
head size, modulated GM maps were divided by intracranial volume. 
Classification approaches 
Two machine learning approaches were used for classification: a 
support vector machine (SVM) and a convolutional neural network 
(CNN). 
Support vector machine (SVM) 
An SVM with a linear kernel was used as this approach previously 
showed good performance using voxel-based features for AD classifi-
cation. (Klöppel et al., 2008; Cuingnet et al., 2011; Bron et al., 2014; 
Bron et al., 2015). The c-parameter was optimized with 5-fold cross- 
validation on the training set. Input features, i.e. voxel values of the 
pre-processed images within a brain mask, were normalized to zero 
mean and unit variance based on the training set. The classifier was 
implemented using Scikit-Learn. 
To gain insight into the classifications, we calculated statistical sig-
nificance maps (p-maps) that show which features contributed to the 
SVM decision. These maps were computed using an analytical expres-
sion that approximates permutation testing (Gaonkar et al., 2015). 
Clusters of significant voxels were obtained using a p-value threshold of 
α⩽0.05. P-maps were not corrected for multiple comparisons, as per-
mutation testing has a low false-positive rate (Gaonkar and Davatzikos, 
2013). 
Convolutional neural network (CNN) 
An all convolutional neural network was used (Springenberg et al., 
2015), which is a fully convolutional network (FCN) architecture that 
uses standard convolutional layers with stride two instead of the pooling 
layers used in most CNNs. This approach was chosen as it has previously 
shown good classification performance for AD based on structural MRI 
(Cui and Liu, 2019; Basaia et al., 2019). The used architecture is shown 
in Fig. 1.4 Specifically, the network was built of 7 blocks consisting of a 
3D convolutional layer (filter size 3; stride 1), followed by dropout, 
batch normalization (BN), and a rectified linear unit (ReLU) activation 
function, succeeded by a second 3D convolutional layer (filter size 3; 
stride 2), dropout, BN, and ReLU activation (Cui and Liu, 2019; Basaia 
et al., 2019). The number of filters changed over blocks: 16 filters in 
block 1, 32 in block 2 and 3, 64 in block 4 and 5, 32 in block 6, and 16 in 
block 7. The final output layer of the network was a softmax activation 
function, providing 2 prediction values (1 per class). The total network 
consisted of 577,498 parameters. For artificially increasing the training 
data set and for removing the class imbalance, data augmentation was 
used. The training set was augmented to 1000 samples per class based on 
the ‘mixup’ approach (Eaton-Rosen et al., 2018; Zhang et al., 2018). 
Mixup is a data-agnostic augmentation approach that is not based on 
spatial transformations, and therefore does not degrade the spatial 
normalization. Augmented samples were constructed by linearly 
combining two randomly selected images of the same class: a fraction of 
80% of the first image was added to a fraction of 20% of the second 
image. 
The network was compiled with a binary cross-entropy loss function 
Table 2 
Demographics for the PND data set. FU: follow-up time.   
AD SCD MCIc MCInc 
# participants 199 138 48 91 
male/ female 94/ 105 92/ 46 33/ 15 56/ 35 
age (y; mean±std)  73.1 ± 9.6  63.2 ± 10.3  70.4 ± 7.9  68.8 ± 12.6  
FU (y; mean±std)  N.A. N.A. 2.7 ± 1.2  2.2 ± 0.8   
4 Figure created with https://alexlenail.me/NN-SVG 
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and Adam optimizer (learning rate = 0.001, epsilon = 1e-8, decay =
0.0). To facilitate a stable convergence, learning rate followed a step 
decay schedule, i.e. after each ten epochs the learning rate was divided 
by two. The dropout rate was set to 20%. Data was propagated through 
the network with a batch size of 4. Input images were normalized to zero 
mean and unit variance based on the augmented training set. A vali-
dation set was created by randomly splitting 10% of the training data 
which was not used for training but only for regularization by early 
stopping, i.e. training was stopped when the validation AUC had not 
increased for 20 epochs. The model of the epoch with the highest vali-
dation AUC was selected as final model. Implementation was based on 
Keras and Tensorflow. 
To gain insight into the classifications, we made saliency maps that 
show which parts of the brain contributed the most to the prediction of 
the CNN, i.e. which voxels lead to increase/decrease of prediction score 
when changed. Saliency maps were made using guided back-
propagation, changing the activation function of the output layers from 
softmax to linear activations (Springenberg et al., 2015). Maps were 
averaged over correctly classified AD patients (Rieke et al., 2018). 
Analysis and statistics 
Classification performance was quantified by the area under the 
curve (AUC) and accuracy. For AD-CN classification, the data of the 
ADNI AD and CN groups were randomly split for 20 iterations preserving 
relative class sizes in each training and testing sample, using 90% for 
training and 10% for testing. Random splits were the same for both SVM 
and CNN. In each iteration, classification model parameters were opti-
mized on the training set as explained above. The models were opti-
mized solely on the training set; the test set was used only for evaluation 
of the final model. Ninety-five percent confidence intervals (95%CI) for 
the mean performance measures were constructed using the corrected 
resampled t-test based on the 20 cross-validation iterations, thereby 
taking into account that the samples in the cross-validation splits were 
not statistically independent (Nadeau and Bengio, 2003). 
Subsequently, we retrained classifiers using all AD and CN partici-
pants from the ADNI as training set. These retrained classifiers were used 
for visualization and their performance was evaluated on three inde-
pendent test sets: ADNI MCIc-MCInc, PND AD-SCD, and PND MCIc- 
MCInc. 95%CIs were obtained based on 500 bootstrap samples of the 
test set. Significant differences between classifiers were assessed using 
the non-parametric McNemar Chi-square test (Dietterich, 1998) 
(α < 0.013 after Bonferroni correction for 4 comparisons in each test 
set). 
Trained models, lists of included subjects and all code used in 
preparation of this article are available from https://gitlab.com/radiolo 
gy/neuro/bron-cross-cohort3. 
Results 
Cross-validation performance for the ADNI AD-CN classification is 
shown in Fig. 2. For SVM, the AUC using modulated GM maps (0.940,
95%CI: 0.924 − 0.955) was higher than the AUC using T1w images 
(0.801,95%CI: 0.765 − 0.837). For CNN, the same effect was observed, 
with modulated GM maps yielding a higher AUC (0.933, 95%CI: 
0.918 − 0.948) than T1w images (0.898, 95%CI: 0.875 − 0.920), albeit 
here with overlapping confidence intervals. For classification based on 
modulated GM maps, the AUC for SVM (0.940, 95%CI: 0.924 − 0.955) 
was similar to that of CNN (0.933, 95%CI: 0.918 − 0.948). Accuracy 
measures showed the same patterns. 
The performance of the classifiers trained on all ADNI AD and CN 
data to predict MCI conversion is shown in Fig. 3. While AUCs with both 
SVM and CNN were slightly higher for modulated GM maps than for 
T1w images, the accuracy measures showed similar performance for 
both inputs. Using modulated GM maps, performance for SVM (AUC =
0.756, 95%CI: 0.720 − 0.788; accuracy = 0.695, 95%CI: 0.665 − 0.723) 
was higher than for CNN (AUC = 0.742, 95%CI: 0.709 − 0.776); accu-
racy = 0.658, 95%CI: 0.628 − 0.690). This difference was significant 
Table 3 
An overview of T1-weighted imaging protocols in the PND data set from eight centers. All sequences were 3D and used gradient recalled echo (GRE). TFE: turbo field 
echo, FSPGR: fast spoiled GRE, TFL: turboflash, MPRAGE: magnetization prepared rapid gradient echo, MP: magnetization prepared, SS: steady state, SP: spoiled, IR: 
inversion recovery, Sag: sagittal, Cor: Coronal, Ax: axial, TE: echo time, TR: repetition time, TI: inversion time.  
Field strength 3T 1.5T    
Vendor Philips GE Siemens Philips GE Siemens    
Number of scans 195 60 70 1 122 40 1 6 1 32 28    
Sequence name TFE GRE GRE GRE FSPGR MPRAGE GRE FSPGR FSPGR TFL 
MPRAGE 
MPRAGE    
Sequence variant MP MP MP MP SS/SP IR/SP/ 
MP 
MP SS/SP SS/SP IR/SP/MP IR/SP/ 
MP    
Plane Sag Sag Sag Cor Sag Sag Sag Sag Ax Sag Sag    
Slice thickness 
(mm) 
1 1 1 1.4 1 1 2 1.6 1.6 1 1    
In-plane (mm*mm) 1*1 0.78*0.78 0.5*0.5 0.88*0.88 0.94*0.94 1*1 0.47*0.47 0.47*0.47 1*1 1*1 0.5*0.5    
TE (ms) 4.2 4.6 3.5 4.6 3 4.7 4.6 2.1 4.2 3 3.7    
TR (ms) 8.1 9.9 9 9.6 7.8 2300 15 7.1 8.3 2000 2700    
TI (ms) N. 
A. 
N.A. N.A. N.A. 450 1100 N.A. 450 450 1100 950     
Fig. 1. CNN architecture3.  
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according to McNemar’s test (p < 0.01). 
The performance of external validation, i.e. the application of the 
classifiers in the PND data set, is shown in Fig. 4. For AD-SCD diagnosis, 
the AUC for SVM was 0.896 (95%CI: 0.855 − 0.932) and that for CNN 
was 0.876 (95%CI: 0.836 − 0.913). Both AUC and accuracy followed the 
same patterns as in ADNI: SVM and CNN showed similar performance 
and modulated GM maps yielded higher classification performance than 
minimally processed T1w images (McNemar’s test; p < 0.01 for SVM, 
p = 0.01 for CNN). Performances were however slightly lower; PND 
confidence intervals for AUC (but not for accuracy) overlapped with 
those of ADNI. 
For prediction of MCI conversion in PND, classification performance 
was also lower than that in ADNI. For the GM modulated maps, the AUC 
for CNN was 0.702 (95%CI: 0.624 − 0.786) and that for SVM was 0.665 
(95%CI: 0.576 − 0.760). Confidence intervals were relatively large and 
overlapped with those in the ADNI data. No significant differences be-
tween classifiers and between pre-processing approaches were seen. 
Brains regions that contributed to the classifications are visualized 
using SVM p-maps in Fig. 5 and using CNN saliency maps in Fig. 6. The 
SVM p-map for the minimally processed T1w images showed small 
clusters of significant voxels, mainly located in the medial temporal lobe 
(hippocampus), around the ventricles and at larger sulci at the outside of 
the brain. For modulated GM maps, clusters of significant voxels in the 
p-map were larger and predominantly visible in the hippocampus. In 
addition, smaller clusters were located in the rest of the temporal lobe 
and the cerebellum. CNN saliency maps showed a very limited contri-
bution of the temporal lobe. Instead, the saliency map for the T1w im-
ages mainly showed contribution of voxels at the edge of the brain, in 
white matter regions around the ventricles and in the cerebellum. For 
modulated GM maps, clusters of contributing voxels were located in the 
subcortical structures, the white matter around the ventricles and the 
cerebellum. 
Discussion 
We performed a comparative study focusing on the generalizability 
of diagnostic and predictive performance of machine learning based on 
MRI data of the ADNI research cohort, to the PND multi-center data set 
representing a tertiary memory clinic population. Both cross-validation 
and external validation results for AD-CN diagnosis showed similar 
performance using the used deep learning classifier and conventional 
classifier. Both approaches significantly benefited from the use of 
modulated GM maps instead of raw T1w images. Application to MCI 
conversion prediction yielded higher performance for SVM than for CNN 
in ADNI, but this was not seen in PND. Performances were in line with 
the state-of-the-art (Rathore et al., 2017; Wen et al., 2020; Ansart et al., 
2021). For MCI conversion prediction, Ansart et al., 2021 showed that 
performance of current methods converges to an AUC of about 75% as 
the number of subjects increases, which aligns with our results. 
While in many medical imaging applications CNNs convincingly 
outperformed conventional classifiers (Litjens et al., 2017), our results 
Fig. 2. Cross-validation performance for classification of the Alzheimer’s dis-
ease patients (AD) and controls (CN) of the ADNI data set expressed by (a) area 
under-the-ROC–curve (AUC) and (b) accuracy. Performance is shown for SVM 
and CNN classifiers using two inputs: minimally processed T1w scans and 
modulated GM images. Error bars indicate 95%CIs. 
Fig. 3. Classification performance of patients with mild cognitive impairment (MCI) that do or do not convert to Alzheimer’s disease (MCIc vs MCInc) in the ADNI 
data set expressed by (a) area under-the-ROC–curve (AUC) and (b) accuracy. Performance is shown for SVM and CNN classifiers using two inputs: minimally 
processed T1w scans and modulated GM images. Error bars indicate 95%CIs. P-values for significant differences are shown in (b). 
E.E. Bron et al.                                                                                                                                                                                                                                  
NeuroImage: Clinical 31 (2021) 102712
6
showed similar performance for CNN and SVM, which confirms the 
findings by Wen et al., 2020. Other CNN designs could possibly improve 
on this, but we made an effort to follow the state-of-the-art for CNN 
design. Promising developments to further improve performance could 
come from changes in network architecture (e.g., successful standard 
architectures like InceptionNet or ResNet, adversarial training, 
discriminative auto-encoders) and improvements in data collection and 
handling (e.g., larger datasets to learn more complex models, or pre-
training on other collections of brain imaging data). In addition, data 
augmentation could play a role in further improvement. While a 
strength of the mix-up approach is that it is data-agnostic, an augmen-
tation approach using for example prior knowledge may have added 
value. This work shows that the need for dedicated pre-processing is 
lower for CNN than for SVM, but nevertheless has an added value for the 
performance. While we evaluated only one implementation of the pre- 
processing procedure (Bron et al., 2014), we expect that alternative 
implementations (e.g. SPM12, FSL-VBM) could have slightly changed 
results but would have led to the same conclusions. With sufficiently 
large datasets the need for dedicated pre-processing including spatial 
normalization may reduce. 
Although SVM and CNN classifiers yielded similar performance, their 
visualizations showed different brain regions to be involved in the 
classification. SVM significance maps showed a clear contribution of the 
hippocampus and medial temporal lobe as previously shown and ex-
pected based on prior knowledge (Bron et al., 2017). CNN saliency maps 
showed involvement of subcortical structures, regions prone to white 
matter hyperintensities and the cerebellum. For both classifiers, classi-
fication based on minimally processed T1w images showed voxels at the 
Fig. 4. Classification performance on the PND data set: (a) area under-the-ROC–curve (AUC) and (b) accuracy. Classifiers were trained on ADNI AD-CN and applied 
to PND AD-SCD (left figures) and PND MCIc-MCInc (right figures). Performance is shown for SVM and CNN classifiers using two inputs: minimally processed T1w 
scans and modulated GM images. Error bars indicate 95%CIs. P-values for significant differences are shown in (b). 
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edge of the brain to be involved, which is expected as only similarity 
transformation to template space had been performed. In addition to the 
brain edges, the CNN classifier, which outperformed the SVM for these 
minimally processed input images, also highlights regions similar to 
those shown by the saliency map for the modulated GM images. This 
may implicate that the CNNs non-linear operations, in contrast to the 
linear kernel of the SVM, could extract feature maps that partly resemble 
GM modulated maps. The regions highlighted by the CNN saliency maps 
could possibly be related to AD using prior knowledge, but we will 
refrain from over-interpretation here. It is however unexpected that the 
medial temporal lobe is not covered as previously shown with CNN sa-
liency maps on ADNI data (Dyrba et al., 2020; Rieke et al., 2018). Dif-
ferences between the SVM and CNN classifiers in involved brain regions 
could be contributed to both the differences in the classification ap-
proaches as well as to the differences in the used visualization tech-
niques. If the first reason dominates, hence if the classifiers actually use 
different brain regions, combining classifiers into a hybrid approach 
would be an interesting future direction. However, for full under-
standing of brain regions involved in CNN-based classification of AD, 
further research is required. 
This work is one of the few to address how AD classification per-
formance of MRI-based machine learning generalizes to an independent 
cohort (Wen et al., 2020; Hall et al., 2015; Bouts et al., 2019; Archetti 
et al., 2019). On the PND data, the resulting AUC values (0.896 for SVM, 
0.876 for CNN) were competitive with values reported for AD-CN in the 
literature, but still they were 0.04–0.07 lower than those in the ADNI 
cross-validation experiment. The main patterns in the results corre-
sponded between ADNI and PND data, i.e. similar performance for SVM 
and CNN and added value of dedicated MRI processing. For prediction in 
MCI, AUC values in the PND data set were 0.04–0.10 lower than those in 
ADNI. Overall, similar to experiments by Wen et al. (2020) and Hall 
et al. (2015), we observed only a minor performance drop. This largely 
preserved performance could be related to the similarities between the 
ADNI and PND studies that include a multi-center set-up, within-study 
standardization of cognitive protocols, and diagnostic criteria for AD 
(McKhann et al., 1984; McKhann et al., 2011) and MCI (Petersen, 2004). 
The performance reduction could be contributed to differences between 
the studies, such as the MRI protocols (all high resolution T1w, but more 
homogeneous within ADNI than within PND), country of origin (United 
States vs. the Netherlands), control population (a combination of 
cognitively normal and SCD vs. SCD only), MCI population (amnestic 
MCI only vs. a broad MCI group) and patient inclusion criteria (ADNI 
used hard cut-offs on cognitive scores and clinical dementia rating 
whereas PND did not) (Petersen et al., 2010; Aalten et al., 2014). Studies 
that found much worse generalizability in their experiments described 
larger differences in inclusion and diagnostic criteria between training 
data and validation data than we did (Bouts et al., 2019; Wen et al., 
2020). 
A limitation of this study is that the diagnosis was based on clinical 
criteria rather than post-mortem histopathological examination. 
Although diagnosis was typically confirmed by follow-up, it is possible 
that some of the patients were misdiagnosed. An alternative could be to 
use amyloid data from PET imaging or cerebrospinal fluid to classify AD 
pathology instead of relying on the clinical diagnosis (e.g., Son et al., 
2020). In addition, because of the limited availability of diagnostic in-
formation at follow-up in the PND data set, its MCI data is relatively 
small. This is reflected by the large confidence intervals for the perfor-
mance metrics in the prediction task. To maximize the number of PND 
MCI participants, we chose to use the last available time point for final 
diagnosis. As a result the time-to-prediction ranged between 1–5 years, 
whereas for ADNI a fixed time interval of three years is chosen. As time- 
to-prediction is related to predictive performance (Ansart et al., 2021), a 
fixed time interval would be preferred for inter-cohort performance 
comparison. 
While the external validation performance was quite high, as ex-
pected some performance drop was observed. Therefore, research 
focusing on approaches to mitigate such performance drops, such as 
transfer learning, is highly relevant (Wachinger and Reuter, 2016). In 
addition, whereas this work only exploited structural MRI, other works 
have shown that performance can be increased with the use of multi- 
modal inputs, i.e. cognitive test scores, fluid-based biomarker mea-
surements, genetic information and other imaging modalities such as 
PET, diffusion MRI or perfusion MRI (Bron et al., 2017; Ansart et al., 
2021; Venkatraghavan et al., 2019). While multi-modal classification 
Fig. 6. Visualization of the CNN classifiers using guided back-propagation saliency maps based on two inputs: (a) minimally processed T1w images and (b) 
modulated GM maps. Relevance maps were averaged over all correctly classified AD participants and thresholded at 13 of the maximum intensity. 
Fig. 5. Visualization of the SVM classifiers using analytic significance maps (p-maps) based on two inputs: (a) minimally processed T1w images and (b) modulated 
GM maps. 
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would therefore be a logical and important extension, this may also lead 
to a decrease of generalizability as chances of differences between 
studies increase with multiple modalities. 
In conclusion, classification performance of ADNI data generalized 
well to the multi-center PND biobank cohort representing tertiary 
memory clinic patients, with only a minor drop in performance. Con-
ventional SVM classifiers and deep learning approaches using CNN 
showed comparable results, and both methods benefited from dedicated 
MRI processing using GM modulated maps. We hope that external 
validation results like those presented here will contribute to setting 
next steps towards the implementation of machine learning in clinical 
practice for aiding diagnosis and prediction. 
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